AQW051   Click here for help

GtoPdb Ligand ID: 7371

Synonyms: AQW 051 | AQW-051 | VQW 765 | VQW-765 | VQW765
Compound class: Synthetic organic
Comment: AQW051 is an α7 nicotinic acetylcholine receptor (nAChR) partial agonist from Novartis that was proposed as an oral treatment for cognitive deficits in schizophrenia, Alzheimer's, and Parkinson's diseases [1,3]. The structure was first disclosed during the March 2014 ACS meeting. AQW051 was later re-named as VQW-765 having been licensed to Vanda Pharmaceuticals.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 25.36
Molecular weight 294.17
XLogP 3.57
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1ccc(cc1)c1ccc(cn1)OC1CN2CCC1CC2
Isomeric SMILES Cc1ccc(cc1)c1ccc(cn1)O[C@H]1CN2CCC1CC2
InChI InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
InChI Key NPDLTEZXGWRMLQ-IBGZPJMESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
AQW051 was progressed as a clinical candidate with potential to treat neurological conditions such as schizophrenia, Alzheimer's, and Parkinson's diseases. Development programmes for Alzheimer's and Parkinson's were discontinued in 2009 and 2016, respectively. The compound was later repositioned by Vanda Pharmaceuticals (as VQW-765) for potential to ameliorate social/performance anxiety, however having missed the primary endpoint of a Phase 3 trial in adults with social anxiety disorder, the programme was put on hold in fall 2026.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01474421 Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Phase 2 Interventional Novartis 5
NCT04800237 Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety Phase 2 Interventional Vanda Pharmaceuticals
NCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder Phase 3 Interventional Vanda Pharmaceuticals